Cargando…

Phytochemicals and PI3K Inhibitors in Cancer—An Insight

In today's world of modern medicine and novel therapies, cancer still remains to be one of the prime contributor to the death of people worldwide. The modern therapies improve condition of cancer patients and are effective in early stages of cancer but the advanced metastasized stage of cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Suvarna, Vasanti, Murahari, Manikanta, Khan, Tabassum, Chaubey, Pramila, Sangave, Preeti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736021/
https://www.ncbi.nlm.nih.gov/pubmed/29311925
http://dx.doi.org/10.3389/fphar.2017.00916
_version_ 1783287311998386176
author Suvarna, Vasanti
Murahari, Manikanta
Khan, Tabassum
Chaubey, Pramila
Sangave, Preeti
author_facet Suvarna, Vasanti
Murahari, Manikanta
Khan, Tabassum
Chaubey, Pramila
Sangave, Preeti
author_sort Suvarna, Vasanti
collection PubMed
description In today's world of modern medicine and novel therapies, cancer still remains to be one of the prime contributor to the death of people worldwide. The modern therapies improve condition of cancer patients and are effective in early stages of cancer but the advanced metastasized stage of cancer remains untreatable. Also most of the cancer therapies are expensive and are associated with adverse side effects. Thus, considering the current status of cancer treatment there is scope to search for efficient therapies which are cost-effective and are associated with lesser and milder side effects. Phytochemicals have been utilized for many decades to prevent and cure various ailments and current evidences indicate use of phytochemicals as an effective treatment for cancer. Hyperactivation of phosphoinositide 3-kinase (PI3K) signaling cascades is a common phenomenon in most types of cancers. Thus, natural substances targeting PI3K pathway can be of great therapeutic potential in the treatment of cancer patients. This chapter summarizes the updated research on plant-derived substances targeting PI3K pathway and the current status of their preclinical studies and clinical trials.
format Online
Article
Text
id pubmed-5736021
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57360212018-01-08 Phytochemicals and PI3K Inhibitors in Cancer—An Insight Suvarna, Vasanti Murahari, Manikanta Khan, Tabassum Chaubey, Pramila Sangave, Preeti Front Pharmacol Pharmacology In today's world of modern medicine and novel therapies, cancer still remains to be one of the prime contributor to the death of people worldwide. The modern therapies improve condition of cancer patients and are effective in early stages of cancer but the advanced metastasized stage of cancer remains untreatable. Also most of the cancer therapies are expensive and are associated with adverse side effects. Thus, considering the current status of cancer treatment there is scope to search for efficient therapies which are cost-effective and are associated with lesser and milder side effects. Phytochemicals have been utilized for many decades to prevent and cure various ailments and current evidences indicate use of phytochemicals as an effective treatment for cancer. Hyperactivation of phosphoinositide 3-kinase (PI3K) signaling cascades is a common phenomenon in most types of cancers. Thus, natural substances targeting PI3K pathway can be of great therapeutic potential in the treatment of cancer patients. This chapter summarizes the updated research on plant-derived substances targeting PI3K pathway and the current status of their preclinical studies and clinical trials. Frontiers Media S.A. 2017-12-14 /pmc/articles/PMC5736021/ /pubmed/29311925 http://dx.doi.org/10.3389/fphar.2017.00916 Text en Copyright © 2017 Suvarna, Murahari, Khan, Chaubey and Sangave. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Suvarna, Vasanti
Murahari, Manikanta
Khan, Tabassum
Chaubey, Pramila
Sangave, Preeti
Phytochemicals and PI3K Inhibitors in Cancer—An Insight
title Phytochemicals and PI3K Inhibitors in Cancer—An Insight
title_full Phytochemicals and PI3K Inhibitors in Cancer—An Insight
title_fullStr Phytochemicals and PI3K Inhibitors in Cancer—An Insight
title_full_unstemmed Phytochemicals and PI3K Inhibitors in Cancer—An Insight
title_short Phytochemicals and PI3K Inhibitors in Cancer—An Insight
title_sort phytochemicals and pi3k inhibitors in cancer—an insight
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736021/
https://www.ncbi.nlm.nih.gov/pubmed/29311925
http://dx.doi.org/10.3389/fphar.2017.00916
work_keys_str_mv AT suvarnavasanti phytochemicalsandpi3kinhibitorsincanceraninsight
AT muraharimanikanta phytochemicalsandpi3kinhibitorsincanceraninsight
AT khantabassum phytochemicalsandpi3kinhibitorsincanceraninsight
AT chaubeypramila phytochemicalsandpi3kinhibitorsincanceraninsight
AT sangavepreeti phytochemicalsandpi3kinhibitorsincanceraninsight